RYTMONORM TABLET 150 mg

Pays: Singapour

Langue: anglais

Source: HSA (Health Sciences Authority)

Ingrédients actifs:

PROPAFENONE HCl

Disponible depuis:

ABBOTT LABORATORIES (SINGAPORE ) PRIVATE LIMITED

Code ATC:

C01BC03

Dosage:

150 mg

forme pharmaceutique:

TABLET, FILM COATED

Composition:

PROPAFENONE HCl 150 mg

Mode d'administration:

ORAL

Type d'ordonnance:

Prescription Only

Fabriqué par:

Benta Lyon

Statut de autorisation:

ACTIVE

Date de l'autorisation:

1988-04-26

Notice patient

Updated 23-Jun-2014 
Rytmonorm
®
 150 mg · Rytmonorm
®
 300 mg  

1. NAME OF THE MEDICINAL PRODUCT 
Rytmonorm
®
 tablet 150mg 
Rytmonorm
®
 tablet 300mg 

2. QUALITATIVE AND QUANTITATIVECOMPOSITION 
One Rytmonorm
®
 tablet 150 mg contains 150 mg propafenone hydrochloride.  
One Rytmonorm
®
 tablet 300 mg contains 300 mg propafenone hydrochloride.  

3. PHARMACEUTICAL FORM 
White to off white film coated tablets, biconvex. 

4. CLINICAL PARTICULARS 
4.1. THERAPEUTIC INDICATIONS 
Symptomatic supraventricular tachyarrhythmias warranting treatment,
such as AV junctional
tachycardias, supraventricular tachycardias in 
patients with WPW syndrome or paroxysmal
atrial fibrillation. Serious symptomatic ventricular
tachyarrhythmias if life-threatening or 
necessitating treatment in the judgement of the physician.  

4.2. POSOLOGY AND METHOD OF ADMINISTRATION 
The individual maintenance dose should be determined under
cardiological surveillance including ECG monitoring
and repeated blood 
pressure control (stabilization phase) unless
otherwise prescribed by the physician.  

For initial and maintenance treatment a daily dose of 450-600
mg divided in two or three
doses per day (one 150 mg Rytmonorm coated tablet 
three times daily or up to one 300 mg Rytmonorm coated tablet
twice daily) is recommended. Occasionally an increase of the
daily dose to 
900 mg may be necessary (one 300
mg Rytmonorm coated tablet three times
daily or two 150 mg Rytmonorm coated tablets three times 
daily).  

These data apply to patients with a body weight of about
70 kg. The daily doses should be
reduced accordingly for patients with a lower body 
weight.   Dose increases should not be attempted
until the patient has been receiving treatment for
three to four days.   
This daily dose should be exceeded only in
exceptional circumstances and unde

Résumé des caractéristiques du produit

Updated 21 May 2020
Rytmonorm
®
150 mg
1. NAME OF THE MEDICINAL PRODUCT
Rytmonorm
®
tablet 150mg
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
One Rytmonorm
®
tablet 150 mg contains 150 mg propafenone hydrochloride.
3. PHARMACEUTICAL FORM
White to off white film coated tablets, biconvex.
4. CLINICAL PARTICULARS
4.1. THERAPEUTIC INDICATIONS
Symptomatic supraventricular tachyarrhythmias warranting treatment,
such as AV junctional tachycardias, supraventricular tachycardias in
patients with WPW syndrome or paroxysmal atrial fibrillation. Serious
symptomatic ventricular tachyarrhythmias if life-threatening or
necessitating
treatment in the judgement of the physician.
4.2. POSOLOGY AND METHOD OF ADMINISTRATION
The individual maintenance dose should be determined under
cardiological surveillance including ECG monitoring and repeated blood
pressure
control (stabilization phase) unless otherwise prescribed by the
physician.
For initial and maintenance treatment a daily dose of 450-600 mg
divided in two or three doses per day (one 150 mg Rytmonorm coated
tablet
three times daily) is recommended. Occasionally an increase of the
daily dose to 900 mg may be necessary (two 150 mg Rytmonorm coated
tablets three times daily).
These data apply to patients with a body weight of about 70 kg. The
daily doses should be reduced accordingly for patients with a lower
body
weight. Dose increases should not be attempted until the patient has
been receiving treatment for three to four days.
This daily dose should be exceeded only in exceptional circumstances
and under strict cardiological control.
In those patients in whom significant widening of the QRS complex,
prolonging of the PR interval or second or third degree AV block
occurs, a
dose reduction should be considered.
Particularly in the elderly and in patients with marked previous
myocardial damage (relevant impairment of left ventricular function or
structural
myocardial disease), the first dose increase should take place after 5
to 8 days of therapy.
When prescribing propafenone